Detalles de la búsqueda
1.
In vitro efficacy of humanized regimen of flomoxef against extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Antimicrob Agents Chemother
; 67(9): e0025823, 2023 09 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610203
2.
Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.
Antimicrob Agents Chemother
; 67(7): e0019423, 2023 07 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37347188
3.
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates.
Antimicrob Agents Chemother
; 67(12): e0034623, 2023 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37971240
4.
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
J Antimicrob Chemother
; 78(8): 2019-2027, 2023 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37390312
5.
In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
J Antimicrob Chemother
; 78(4): 983-990, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36775993
6.
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Clin Infect Dis
; 75(6): 1081-1084, 2022 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35148378
7.
In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019.
Antimicrob Agents Chemother
; 66(2): e0199021, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34807757
8.
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
Antimicrob Agents Chemother
; 66(10): e0061822, 2022 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36154614
9.
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing.
J Antimicrob Chemother
; 77(6): 1662-1669, 2022 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35289853
10.
In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia.
Antimicrob Agents Chemother
; 65(4)2021 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33526491
11.
Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models.
J Antimicrob Chemother
; 76(10): 2615-2621, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34212183
12.
Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model.
Antimicrob Agents Chemother
; 64(11)2020 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32900685
13.
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.
Clin Infect Dis
; 69(Suppl 7): S544-S551, 2019 11 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31724049
14.
Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model.
Antimicrob Agents Chemother
; 63(2)2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30420477
15.
In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models.
Antimicrob Agents Chemother
; 63(9)2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31262762
16.
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.
Antimicrob Agents Chemother
; 62(2)2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158270
17.
Erratum for Karlowsky et al., "In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019".
Antimicrob Agents Chemother
; 67(6): e0042723, 2023 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154749
18.
In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria.
Antimicrob Agents Chemother
; 62(1)2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29061741
19.
Stability and low induction propensity of cefiderocol against chromosomal AmpC ß-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
J Antimicrob Chemother
; 73(11): 3049-3052, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30188999
20.
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
Antimicrob Agents Chemother
; 61(11)2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28848004